[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 23, Issue 3 (Bimonthly 2019) ::
Feyz 2019, 23(3): 253-260 Back to browse issues page
The effects of cytotoxic concentration of testosterone, progesterone and estradiol on anti-metastasis CD82/KAI1 expression level in brain glioblastoma cancer cells
Noushin Farahmandlou * , Sahar Sharifi , Sajad Gomar
Department of Basic Sciences, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, I. R. Iran. , n.farahmanlou@yahoo.com
Abstract:   (341 Views)
Background: Studies have shown that sexual steroids can affect metastasis in cancer cells of nervous system at cellular and molecular level; however, the cellular and molecular mechanism of sexual steroids action on metastasis in cancer cells of nervous system is unclear in many cases. This study aimed at investigating the effects of cytotoxic dose of testosterone, progesterone and estradiol on anti-metastasis CD82/KAI1 genes expression levels in brain glioblastoma cells (A172).
Materials and Methods: In this laboratory-experimental study, A172 cells were obtained from Pasteur institute and divided into control group and groups exposed to cytotoxic dose of testosterone, progesterone, and estradiol. Real time PCR also was used to evaluate CD82/KAI1 genes expression levels. The data were statistically analyzed between groups using ANOVA.
Results: CD82/KAI1 genes expression level significantly decreased in A172 cells exposed to cytotoxic dose of testosterone, progesterone and estradiol (P<0.001, P<0.05 and P<0.001, respectively).
Conclusion: The cytotoxic dose of testosterone, progesterone and estradiol can decrease the anti-metastatic CD82/KAI1 gene expression level and therefore may increase metastasis potential in brain cancer cells.
Keywords: Testosterone, Progesterone, Estradiol, Glioblastoma, CD82/KAI1
Full-Text [PDF 287 kb]   (45 Downloads)    
Type of Study: Research | Subject: General
Received: 2018/11/5 | Accepted: 2019/05/20 | Published: 2019/07/31
References
1. Rodriguez KM, Pastuszak AW, Khera M. The Role of Testosterone Therapy in the Setting of Prostate Cancer. Curr Urol Rep 2018; 19(8): 67.
2. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 2013; 34(1): 130-62.
3. Del Pup L, Berretta M, Di Francia R, Cavaliere C, Di Napoli M, Facchini G, et al. Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk. Anticancer Drugs 2014; 25(7): 745-50.
4. Divekar SD, Tiek DM, Fernandez A, Riggins RB. Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renaissance? Nucl Recept Signal 2016; 21: 14.
5. Wesołowska M, Pawlik P, Jagodziński PP. The clinicopathologic significance of estrogen receptors in human gastric carcinoma. Biomed Pharmacother 2016; 83: 314-22.
6. Merritt RL, Foran CM. Influence of persistent contaminants and steroid hormones on glioblastoma cell growth. J Toxicol Environ Health 2007; 70(1): 19-27.
7. Johann S, Beyer C. Neuroprotection by gonadal steroid hormones in acute brain damage requires cooperation with astroglia and microglia. J Steroid Biochem Mol Biol 2013, 137: 71-81.
8. Li S, Hu Y, Zhao J, Zhao Y,Sun J,Yang Y, et al. MicroRNA-34a induces apoptosis in the human glioma cell line, A172, through enhanced ROS production and NOX2 expression. Biochem Biophys Res Commun 2014; 31: 444(1): 6-12.
9. Ornstein KA, Liu B, Schwartz RM, Smith CB, Alpert N, Taioli E. Cancer in the context of aging: Health characteristics, function and caregiving needs prior to a new cancer diagnosis in a national sample of older adults. J Geriatr Oncol 2019; pii: S1879-4068(18): 30475-2.
10. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019; 14(1): 26-38.
11. Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. Cancer Lett 2006; 240(1): 143–7.
12. Dawe D, Greenspoon J, Ellis P. Brain Metastases in Non-Small-Cell Lung Cancer. Clin Lung Cancer 2014; 15(4): 249-57.
13. Thomas L, Honnorat J. Brain metastases epidemiology, diagnosis and imagery. Rev Prat 2014; 64(5): 668-73.
14. Jazayeri S, Rahimi-MovagharV, Shokraneh F, Saadat S,Ramezani R. Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev 2013; 14(6): 3979-85.
15. Akhavan A, Binesh F, Heidari S. Survival of brain metastatic patients in Yazd, Iran. Asian Pac J Cancer Prev 2014; 15(8): 3571- 4.
16. Madhusoodanan S, Ting MB, Farah T, Ugur U. Psychiatric aspects of brain tumors: A review. World J Psychiatry 2015; 5(3): 273-85.
17. Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, Bidere N. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep 2011; 12(5): 470–6.
18. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010; 12: 26–33.
19. Robins HI, Chang S, Butowski N, Mehta M. Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep 2007; 9: 66–70.
20. Haque A, Banik NL, Ray SK. Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci 2011; 98: 187-234.
21. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26(8): 756-84.
22. Fonnet E, Bleeker, Remco J, Molenaar, Sieger Leenstra. Recent advances in the molecular understanding of glioblastoma. J Neurooncol 2012; 108(1): 11–27.
23. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology 2011; 13(6): 566-79.
24. Friesen C, Hormann I, Roscher M, Fichtner I, Alt A, Hilger R. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle 2014; 13(10): 1560-70.
25. Anderson KM, Ondrey F, Harris JE. ETYA, a pleotropic membrane-active arachidonic acid analogue affects multiple signal transduction pathways in cultured transformed mammalian cells. Clin Biochem 1992; 25(1): 1-9.
26. Gründker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol 2017; 8: 187.
27. Finlay-Schultz J, Sartorius CA. Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. J Mammary Gland Biol Neoplasia 2015; 20(1-2): 39-50.
28. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015: ERC-15.
29. Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res 2011; 51(3): 259-69.
30. Ramachandran B, Stell A, Maravigna L, Maggi A, Ciana P. Novel insights on imaging sex-hormone dependent tumourigenesis in vivo. Endocr Relat Cancer 2011: ERC-10.
31. Cooper C, Guo J, Yan Y, Chooniedass-Kothari S, Hube F, Hamedani MK, et al. Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Res 2009; 37(13): 4518-31.
32. Moul JW. Hormone naïve prostate cancer: predicting and maximizing response intervals. Asian J Androl 2015; 17(6): 929.
33. Secreto G. Urinary testosterone values in patients with ovarian metastases from breast cancer. Tumori J 1977; 63(5): 457-62.
34. Jeon SY, Hwang KA, Choi KC. Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development. J Steroid Biochem Mol Biol 2016; 158: 1-8.
35. Tania Hernandez-Hernandez O, Camacho-Arroyo I. Regulation of gene expression by progesterone in cancer cells: effects on cyclin D1, EGFR and VEGF. Mini-Rev Med Chem 2013; 13(5): 635-42.
36. Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, et al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review. Cancer Metastasis Rev 2016; 35(3): 427-37.
37. Li MQ, Hou XF, Lv SJ, Meng YH, Wang XQ, Tang CL, et al. CD82 gene suppression in endometrial stromal cells leads to increase of the cell invasiveness in the endometriotic milieu. J Mol Endocrinol 2011; 47(2): 195-208.
38. Lin KH, Wang WJ, Wu YH, Cheng SY. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its α-receptor. Endocrinology 2002; 143(2): 467-75.
39. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, Saadat S, Ramezani R. Epidemiology of primary CNS tumors in Iran: a systematic. Asian Pac J Cancer Prev 2013; 14(6): 3979-85.
40. Li MQ, Hou XF, Lv SJ, Meng YH, Wang XQ, Tang CL, et al. CD82 gene suppression in endometrial stromal cells leads to increase of the cell invasiveness in the endometriotic milieu. J Mol Endocrinol 2011; 47(2): 195-208.
41. Gellersen B, Briese J, Oberndörfer M, Redlin K, Samalecos A, Richter DU, et al. Expression of the metastasis suppressor KAI1 in decidual cells at the human maternal-fetal interface: Regulation and functional implications. Am J Pathol 2007; 170(1): 126-39.
42. Christgen M, Christgen H, Heil C, Krech T, Länger F, Kreipe H, et al. Expression of KAI1/CD82 in distant metastases from estrogen receptor‐negative breast cancer. Cancer Sci 2009; 100(9): 1767-71.
43. Farahmandlou N, Oryan S, Ahmadi R, Eidi A. Association of Testosteroen with colorectal cancer (HT29), Human Glioblastoma (A172) and Human Embryonic Kidney (Hek293) Cells Proliferation. Acta Endocrinol (1841-0987). 2017; 1: 13(2).
44. Aka JA, Zerradi M, Houle F, Huot J, Lin SX. 17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration. Breast Cancer Res 2012; 14(3): R92.
45. Bao J, Cao C, Zhang X, Jiang F, Nicosia SV, Bai W. Suppression of β-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estrogen receptor and Fe65. Mol Cell Biol 2007; 27(4): 1321-33.
46. Kassi E, Moutsatsou P. Glucocorticoid receptor signaling and prostate cancer. Cancer Lett 2011; 302(1): 1-0.
47. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Clin Cancer Res 2001; 61(11): 4386-92.
48. Bao J, Cao C, Zhang X, Jiang F, Nicosia SV, Bai W. Suppression of β-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estrogen receptor and Fe65. Mol Cell Biol 2007; 27(4): 1321-33.
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farahmandlou N, Sharifi S, Gomar S. The effects of cytotoxic concentration of testosterone, progesterone and estradiol on anti-metastasis CD82/KAI1 expression level in brain glioblastoma cancer cells. Feyz. 2019; 23 (3) :253-260
URL: http://feyz.kaums.ac.ir/article-1-3741-en.html


Volume 23, Issue 3 (Bimonthly 2019) Back to browse issues page
مجله علمی پژوهشی فیض ::: دانشگاه علوم پزشکی کاشان KAUMS Journal ( FEYZ )
Persian site map - English site map - Created in 0.06 seconds with 32 queries by YEKTAWEB 3961